Possible glucagon-mediated hypocholesterolemic activity of a nicotinic acid derivative (sorbinicate).
The antilipolytic activity of nicotinic acid was investigated in 7 patients with type II b hyperlipoproteinemia and in 7 with type IV hyperlipoproteinemia treated for two months with a nicotinic acid derivative, sorbinicate (1600 mg daily, ie 1454 mg NA). Before and after treatment the blood levels of total cholesterol and triglycerides were determined and three dynamic tests -- oral glucose tolerance test, insulin test and tolbutamide test -- were done to check in each test the variations in blood glucose, NEFA, insulin (excluding obviously the insulin test), glucagon and growth hormone levels. At the end of the treatment, there was a significant reduction of cholesterol (type IIb and type IV) and of triglycerides (type IV), a marked reduction of the glucagon response, a slight increase in the insulin response and in the basal secretion of the growth hormone. It is suggested that the antilipolytic activity of nicotinic acid (and hence of sorbinicate) is at least partly mediated by an inhibition of glucagon secretion (and/or synthesis).
D000328:Adult; D002784:Cholesterol / Q000097:blood; D005934:Glucagon / Q000097:blood / Q000378:metabolism*; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy*; D006953:Hyperlipoproteinemia Type IV / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009539:Nicotinic Acids / Q000494:pharmacology / Q000627:therapeutic use*; D009765:Obesity / Q000150:complications; D013012:Sorbitol / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood
D009539:Nicotinic Acids; D014280:Triglycerides; C015238:glucitol hexanicotinate; D013012:Sorbitol; D005934:Glucagon; D002784:Cholesterol